Northern Oesophago-Gastric Cancer Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.
Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Br J Surg. 2017 Mar;104(4):401-407. doi: 10.1002/bjs.10425. Epub 2017 Jan 10.
Raised levels of systemic inflammatory markers are associated with poor survival in patients with cancer. The aim of this study was to assess the prognostic value of markers of systemic inflammation in patients with adenocarcinoma of the oesophagus or gastro-oesophageal junction.
Data from a consecutive series of patients undergoing transthoracic oesophagectomy following neoadjuvant therapy at a single centre were analysed. Fibrinogen, albumin, C-reactive protein, leucocyte differential and platelet counts were measured before surgery. The upper quartile (75th percentile) was used as a cut-off for dichotomization. Multivariable regression analysis was performed to identify independent prognostic factors.
A series of 199 patients underwent transthoracic oesophagectomy following neoadjuvant therapy. Univariable analysis indicated that reduced median survival was associated with a raised platelet : lymphocyte ratio (158 or above; 25.6 versus 44·4 months for patients with a normal ratio, P = 0·038) and increased fibrinogen levels (4·9 g/l or above; 22·8 versus 59·9 months for those with a normal level, P = 0·005). On multivariable analysis a combination of one or more markers of systemic inflammation was associated with poorer overall survival (hazard ratio 2·12, 95 per cent c.i. 1·20 to 3·74; P = 0·010).
Preoperative markers of systemic inflammation predict poor outcome in patients undergoing curative treatment for locally advanced oesophageal and gastro-oesophageal adenocarcinoma.
全身性炎症标志物水平升高与癌症患者的生存不良有关。本研究旨在评估全身炎症标志物在食管或胃食管交界处腺癌患者中的预后价值。
对单中心接受新辅助治疗后行经胸食管切除术的连续患者系列数据进行了分析。手术前测量纤维蛋白原、白蛋白、C 反应蛋白、白细胞分类计数和血小板计数。使用四分位数(第 75 个百分位数)作为二分类的截断值。进行多变量回归分析以确定独立的预后因素。
199 例患者接受了新辅助治疗后经胸食管切除术。单变量分析表明,血小板与淋巴细胞比值升高(158 或以上;正常比值患者的中位生存期为 25.6 个月,而比值升高患者为 44.4 个月,P=0.038)和纤维蛋白原水平升高(4.9 g/l 或以上;正常水平患者的中位生存期为 22.8 个月,而升高患者为 59.9 个月,P=0.005)与降低的中位生存期相关。多变量分析显示,一种或多种全身炎症标志物的组合与总体生存较差相关(风险比 2.12,95%置信区间 1.20 至 3.74;P=0.010)。
术前全身炎症标志物可预测接受局部晚期食管和胃食管交界处腺癌根治性治疗患者的预后不良。